Prime Medicine, Inc.

    Jurisdiction
    United States
    ISIN
    US74168J1016 (PRME)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    2 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    6 / 7

    Profile

    Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. Read full profile

    Fundamentals

    Net revenue
    €4.23M
    Gross margin
    27.8%
    EBIT
    -€174.19M
    EBIT margin
    -4,116.6%
    Net income
    -€169.97M
    Net margin
    -4,016.8%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €20.78M +391.0% -€133.90M -21.2%
    €29.71M +43.0% -€143.43M +7.1%
    €2.50M -91.6% -€174.39M +21.6%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    Last dividend amount
    $0.80
    Ex date
    Payment date

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Alphabet Inc. N/A +1.5M $3.30 +$4.95M
    GILLIS STEVEN N/A +3M $3.30 +$10.00M
    NELSEN ROBERT N/A +3M $3.30 +$10.00M

    Investor transactions

    Name Shares Value Last change Change type
    Cathie Wood 3.1M $6.16M -2.1M Sell
    Peter Brown 448K $890.72K +428K Buy

    Earnings Calls

    Add to watchlist

    Notifications